One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January...
* Reuters is not responsible for the content in this press release.
One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 More than 10 years of proven safety with NicoDerm(R) CQ(R), Nicorette(R) and Commit(R) PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) Consumer Healthcare today announced that it sold one million boxes of smoking cessation products in January 2008, which includes NicoDerm CQ patches, Nicorette gum, and Commit lozenges. The New Year is the most popular time for smokers to try and quit, unfortunately, many of them fail without the proper tools and support. With more than 44 million smokers in this country, people need as many safe and effective options as possible to help them quit. Therapeutic nicotine products, including NicoDerm CQ, can double a smoker's chances of quitting and remain smoke-free long-term (6 months and longer). In fact, 45 percent of smokers using NicoDerm CQ were smoke-free at the end of 10 weeks (vs. 18% on placebo, based on a study employing a group and individual behavioral support programs). NicoDerm CQ allows smokers to wean off nicotine gradually and safely. The product is formulated with a patented SmartControl technology to control the release of nicotine and help target cravings. Smokers often experience withdrawal symptoms, such as irritability, mood depression, and nervousness, as well as nicotine cravings, when they abruptly quit smoking. The FDA- approved labeling for NicoDerm CQ and other therapeutic nicotine products states that it reduces these withdrawal symptoms. SmartControl technology ensures that a smoker receive a steady flow of nicotine for 16 or 24 hours (depending on how long a smoker wears the NicoDerm CQ patch). This means the smoker has a continuous defense to fight the nicotine cravings. Since 1996, GlaxoSmithKline Consumer Healthcare's family of over-the- counter smoking cessation products, NicoDerm CQ patch, Nicorette gum and Commit lozenge, and personalized counseling and support resources have helped more than five million smokers quit smoking. Data from more than 100 clinical trials among more than 35,000 people have established the safety and efficacy profile of therapeutic nicotine for successful smoking cessation. These products are available without a doctor's prescription, in flexible dosing options at more than 35,000 retail outlets across the country. "We are thrilled to see so many people trying to get their new year started in a healthy way by quitting smoking. But we know for some people, this is not an easy addiction to break, and we want to remind them of the safe options to wean them off of nicotine -- like NicoDerm CQ -- which are easily available to help support their quit attempts," said Bill Slivka, Vice President Smoking Control, GlaxoSmithKline Consumer Healthcare. To encourage people to quit smoking for the rest of 2008, GSK Consumer Healthcare is offering a free NicoDerm CQ placebo patch or a 20-count box of Nicorette Cinnamon Surge to consumers. The placebo patch is available online at www.NicodermCQ.com. It is intended to show smokers that the NicoDerm CQ patch is easy to use, comfortable and discrete. Nicorette gum is available by calling 1-800-NICORETTE. These offers will help smokers decide whether NicoDerm CQ or Nicorette is the right option for their quit attempt. Quitting smoking is the most important step smokers can take to improve their health -- and it's also one of the most difficult. By developing innovative new products and support systems to improve the quit experience, GSK Consumer Healthcare is working to inspire and enable every smoker to quit. About NicoDerm CQ NicoDerm CQ is the best-selling smoking cessation patch in history and has helped millions of smokers quit. It is also the number one doctor-recommended patch to quit smoking. When used as directed, NicoDerm CQ allows a smoker to gradually adjust to having less nicotine until eventually he doesn't need any at all. NicoDerm CQ step-down therapy is available in three strengths, 7mg, 14mg and 21 mg. About GlaxoSmithKline Consumer Healthcare GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ(R) and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne,(R) Tums(R) and Breathe Right(R). About GlaxoSmithKline GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com. SOURCE GlaxoSmithKline Consumer Healthcare Malesia Dunn, Director, Communications of GlaxoSmithKline Consumer Healthcare, +1-412-200-3544
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- California passes 'yes-means-yes' campus sexual assault bill
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- IBM launches Watson system for research, hopes for breakthroughs
- Family of instructor killed at Arizona gun range does not blame girl